



# Quality-by-Design Is a Tool for Quality Assurance in the Assessment of Enantioseparation of a Model Active Pharmaceutical Ingredient


Dina Aboushady <sup>1</sup>, Maria Kristina Parr <sup>2,\*</sup> and Rasha S. Hanafi <sup>1</sup>

<sup>1</sup> Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt; dina.abou-shady@guc.edu.eg (D.A.); rasha.hanafi@guc.edu.eg (R.S.H.)


<sup>2</sup> Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2 + 4, 14195 Berlin, Germany

\* Correspondence: maria.parr@fu-berlin.de; Tel: +49-(0)-30-838-57-686

Received: 2 October 2020; Accepted: 31 October 2020; Published: 4 November 2020



**Figure S1.** Graphical output of the screening design of TER chiral separation. **(A)** Main Effect Plots for retention time ( $tR_{Last}$ ), **(B)** Main Effect Plots for selectivity ( $\alpha$ ). Steepness of the slope in CMPA type and concentration and buffer concentration indicates the high influence of these studied factors on the responses.



**Figure S2.** Pareto charts expressing the effect of each studied factor on responses: **(A)** Most influential factors affecting  $tR_{Last}$  **(B)** Most influential factors affecting  $\alpha$ .